JPS61212515A - Ointment for hemorrhoid - Google Patents
Ointment for hemorrhoidInfo
- Publication number
- JPS61212515A JPS61212515A JP60053000A JP5300085A JPS61212515A JP S61212515 A JPS61212515 A JP S61212515A JP 60053000 A JP60053000 A JP 60053000A JP 5300085 A JP5300085 A JP 5300085A JP S61212515 A JPS61212515 A JP S61212515A
- Authority
- JP
- Japan
- Prior art keywords
- ointment
- hemorrhoid
- pectin
- drug
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 18
- 239000002674 ointment Substances 0.000 title claims abstract description 18
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- 229920001615 Tragacanth Polymers 0.000 claims abstract description 6
- 239000003883 ointment base Substances 0.000 claims abstract description 6
- 241000416162 Astragalus gummifer Species 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 3
- 229960004194 lidocaine Drugs 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960000458 allantoin Drugs 0.000 abstract description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229960004544 cortisone Drugs 0.000 abstract description 2
- 229930195733 hydrocarbon Natural products 0.000 abstract description 2
- 150000002430 hydrocarbons Chemical class 0.000 abstract description 2
- 239000000196 tragacanth Substances 0.000 abstract 2
- 235000010487 tragacanth Nutrition 0.000 abstract 2
- 229940116362 tragacanth Drugs 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 241001071917 Lithospermum Species 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- -1 etc.) Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 2
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- NNCOOIBIVIODKO-UHFFFAOYSA-N aluminum;hypochlorous acid Chemical compound [Al].ClO NNCOOIBIVIODKO-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】 本発明は痔疾用軟膏に関する。[Detailed description of the invention] The present invention relates to hemorrhoid ointments.
我が国では生活様式や生活環境から痔疾患者が多い。In Japan, many people suffer from hemorrhoids due to their lifestyle and living environment.
痔疾には痔核、痔屡、肛門周囲炎、裂肛などがあるが、
いずれも初期の治療が大事であシ、時期を逸すると治療
が困難となり、外科手術などＫよる入院加療が必要とな
る。Hemorrhoids include hemorrhoids, hemorrhoids, perianitis, anal fissures, etc.
In either case, early treatment is important; if the timing is missed, treatment becomes difficult and requires hospitalization and treatment such as surgery.
本発明の目的は治療効果の高い痔疾用軟膏を提供するこ
とにある。An object of the present invention is to provide an ointment for hemorrhoids that is highly effective in treating hemorrhoids.
本発明の目的物は、ポリビニルアルコール、ペクチン、
メチルセルロース、エチルセルロース。The object of the present invention is polyvinyl alcohol, pectin,
Methylcellulose, ethylcellulose.
ポリビニルピロリドン、プルラ／およびトラガントガム
よりなる群から選んだ１種または２種以上の化合物を常
用の軟膏基剤に配合した痔疾用軟膏である。This is an ointment for hemorrhoids containing one or more compounds selected from the group consisting of polyvinylpyrrolidone, pullula/gum tragacanth, and a commonly used ointment base.
本発明において常用の軟膏基剤とは、油脂類（たとえば
、大豆油、カカオ脂、牛脂、豚脂、硬化油など）、ロウ
類（たとえば、ミツロウ２ ラノリ／など）、炭化水素
類（たとえば、流動パラフィン、ワセリン、パラフィン
、スクワラン、スクワレンなど）、脂肪酸類（たとえば
、ステアリン酸、パルミチン酸、ミリスチン酸など）、
−価アルコール類（タトエハ、セチルアルコール、ステ
アリルアルコール、コレステロ−ルナ、！”）、多価ア
ルコール類（たとえば、プロピレングリコール。Commonly used ointment bases in the present invention include oils and fats (e.g., soybean oil, cacao butter, beef tallow, lard, hydrogenated oil, etc.), waxes (e.g., beeswax 2 lanoli/etc.), hydrocarbons (e.g., liquid paraffin, petrolatum, paraffin, squalane, squalene, etc.), fatty acids (such as stearic acid, palmitic acid, myristic acid, etc.),
-hydric alcohols (tatoeha, cetyl alcohol, stearyl alcohol, cholesteroluna,!''), polyhydric alcohols (e.g. propylene glycol).
グリセリンなど）、エステル類（たとえば、ミリスチン
酸イングロビル、ミリスチン酸オクチルドデシル、パル
ミチン酸イノプロピルなど）、界面活性剤（たとえば、
ポリオキシエチレンソルビタン脂肪酸エステル、ソルビ
タン脂肪酸エステルなど）などからなる。glycerin, etc.), esters (e.g., inglovir myristate, octyldodecyl myristate, inopropyl palmitate, etc.), surfactants (e.g.,
polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, etc.).
本発明の軟膏に用いられる薬物は、抗炎症削代とえば、
コルチゾン、ヒドロコルチゾン、酢酸ヒドロコルチゾン
、デキサメタシン、酢酸デキサメ酸ヒドロコルチゾン、
塩化リゾチーム、グリチルレチン酸、ブフェキサマック
、イブプロフェン。The drugs used in the ointment of the present invention include anti-inflammatory agents such as:
Cortisone, hydrocortisone, hydrocortisone acetate, dexamethacin, hydrocortisone acetate dexamate,
Lysozyme chloride, glycyrrhetinic acid, bufexamac, ibuprofen.
プロメラインなど）、肉芽形成促進剤（たとえば、アラ
ントイン、紫根など）、局所麻酔剤（たとえば、塩酸ジ
プカイン、アミノ安息香酸エチル、リドカイン、塩酸プ
ロ力インなど）、抗ヒスタミン剤（たとえば、ジフェン
ヒドラミン、塩酸ジフェンヒドラミンなど）、止血剤（
たとえば、塩酸ナファゾリン、塩酸フェニレフリンなど
）、殺菌剤（たとえば、塩酸クロルヘキシジン、グルコ
ン酸シロルヘキシ、ジン、塩化デカリニウムなど）、ビ
タミン類（たとえば、酢酸トコフェロール、パルミチン
酸レチノール、エルゴカルシフェロールなど）、血行促
進剤（たとえば、カンフル、メントールなど）、収れん
剤（たとえば、アルミニウムヒドロキシクロリド、酸化
亜鉛など）などをいう。promeline, etc.), granulation promoters (e.g., allantoin, purple root, etc.), local anesthetics (e.g., dipcaine hydrochloride, ethyl aminobenzoate, lidocaine, promelain hydrochloride, etc.), antihistamines (e.g., diphenhydramine, diphenhydramine hydrochloride, etc.) ), hemostatic agent (
(e.g., naphazoline hydrochloride, phenylephrine hydrochloride, etc.), bactericides (e.g., chlorhexidine hydrochloride, silolhexy gluconate, gin, dequalinium chloride, etc.), vitamins (e.g., tocopherol acetate, retinol palmitate, ergocalciferol, etc.), blood circulation promoters. (for example, camphor, menthol, etc.), astringents (for example, aluminum hydroxychloride, zinc oxide, etc.), etc.
本発明の軟膏は、たとえば下記の方法により調製するこ
とができる。The ointment of the present invention can be prepared, for example, by the method described below.
すなわち、前記軟膏基剤成分を８０〜６０℃、好ましく
は約７０℃で融解または分散し、これに所要量の前記の
薬物、添加剤およびその他必要な成分を加えてよく攪拌
した後、攪拌しながら４０〜２０℃、好ましくは約３０
℃まで冷却し、これをチューブ、びんなど常用の容器に
充填する。That is, the ointment base component is melted or dispersed at 80 to 60°C, preferably about 70°C, and the required amount of the drug, additives, and other necessary ingredients are added thereto, stirred well, and then stirred. 40-20℃, preferably about 30℃
Cool to ℃ and fill it into common containers such as tubes and bottles.
このようにして得られた本発明の軟膏は、薬物の痔疾患
部への作用が向上し、痔疾の症状を著しく改善すること
ができる。The ointment of the present invention thus obtained has improved drug action on hemorrhoid diseased areas and can significantly improve hemorrhoid symptoms.
以下、実施例を挙げて本発明を具体的に説明する。The present invention will be specifically described below with reference to Examples.
実施例 １
ワセリン ２ ＆ ５ ｔ、流動パラフィン １０２゜
パラフィン ５２．プラスチベース”ｔＯｆを約７０℃
で溶解分散し、これに酢酸ヒドロコルチゾン １５９．
リドカイン １．Ｏｆ、 塩酸クロルヘキシジン
０．２ｆ、酸化亜鉛 ５．Ｏｆ、 ゴーセノール
ＧＬ０５（商品名、ポリビニルアルコール。Example 1 Vaseline 2 & 5 t, liquid paraffin 102° paraffin 52. Plastibase "tOf about 70℃
Hydrocortisone acetate was added to this to dissolve and disperse.
Lidocaine 1. Of, chlorhexidine hydrochloride 0.2f, zinc oxide 5. Of, Gohsenor
GL05 (trade name, polyvinyl alcohol.
日本合成化学■製） １０ｆ、 ペクチン ３０２を
加えてよく攪拌して分散させた。これを攪拌しながら約
３０℃まで冷却して本発明の軟膏１００？を得た。10f (manufactured by Nippon Gosei Kagaku ■) and Pectin 302 were added and thoroughly stirred to disperse. The ointment of the present invention is cooled to about 30° C. while stirring. I got it.
註）＊：実施例２の註に同じ 実施例 ２ 実施例１に準じて下記処方の軟膏を調製した。Note) *: Same as the note in Example 2 Example 2 An ointment having the following formulation was prepared according to Example 1.
（処 方） プフェキサマソク ５．０２ 酢酸トコフエロール １．０２ メチルセルロース ４２．Ｏｆ ワセリン ３２．Ｏｆ プラスチベース＊２０．Ｏｆ １０ α ０２ 註） ＊：（商品名、ポリエチレン−流動パラフィン。(How to treat) Pufeki Samasoku 5.02 Tocopherol acetate 1.02 Methyl cellulose 42. Of Vaseline 32. Of Plastibase *20. Of 10 α 02 Note) *: (Product name, polyethylene-liquid paraffin.
スクイブ・コーポレーション製） 実施例 ３ 実施例１に準じて下記処方の軟膏を調製した。Manufactured by Squibb Corporation) Example 3 An ointment having the following formulation was prepared according to Example 1.
（処 方）
酢酸プレドニゾロン Ｑ、１１
ジフエンヒドラミン Ｑ、５１塩酸ナフアゾリ
ン α１２
メントール ０．５１
ペクチン １１０Ｆ
メチルセルロース １５．Ｏｆ
エチルセルロース １ａＯｆ
ラノリン １α０タ
ミツロウ ５゜０２硬化ダイズ油
５．０？
ダイズ油 ２α０２
カカオ脂 ５．８り１０ α ０２
実施例 ４
実施例１に準じて下記処方の軟膏を調製した。(Prescription) Prednisolone acetate Q, 11 Diphenhydramine Q, 51 Naphazoline hydrochloride α12 Menthol 0.51 Pectin 110F Methylcellulose 15. Of Ethyl Cellulose 1aOf Lanolin 1α0 Tamizwax 5゜02 Hydrogenated Soybean Oil
5.0? Soybean oil 2α02 Cocoa butter 5.8ri10 α02 Example 4 According to Example 1, an ointment with the following formulation was prepared.
（処 方）
プレドニゾロン α１ｆ塩酸フエニレフ
リン Ｑ、１１紫根エキス
０．１Ｆカンフル ［１７
ｆゴーセノール ＧＬＯ５１Ｑ、Ｏｆ
ペクチン ５−Ｏｆメチルセルロ
ース ５．Ｏｆエチルセルロース
４． Ｏｆポリビニルピロリドン ６．
Ｏｆプルラン ７． Ｏｆトラガ
ントガム ２．０２ワセリン
４５．０ ｔ１０αＯｔ
実施例 ５
実施例１に準じて下記処方の軟膏を調製した。(Prescription) Prednisolone α1f Phenylephrine Hydrochloride Q, 11 Purple Root Extract
0.1F Camphor [17
f Gohsenol GLO51Q, Of Pectin 5-Of Methylcellulose 5. Of ethyl cellulose
4. Of polyvinylpyrrolidone 6.
Of pullulan 7. Of Tragacanth Gum 2.02 Vaseline
45.0 t10αOt Example 5 According to Example 1, an ointment with the following formulation was prepared.
（処 方）
ヒドロコルチゾン ０．３ｆ塩酸クロルヘ
キシジン ０．２ｆポリビニルピロリドン
１［１，Ｏｒゴーセノール Ｇ Ｌ Ｏ５５，Ｏｒ
メチルセルロース １α０１トラガントガム
５．０２ワセリン
５５．５ ｆ流動パラフィン １０
０２パラフイン ４，０２１０（Ｌ
ＯＰ
実施例 ６
実施例１に準じて下記処方の軟膏を調製した。(Prescription) Hydrocortisone 0.3f Chlorhexidine Hydrochloride 0.2f Polyvinylpyrrolidone
1 [1, Or Gohsenol G L O55, Or Methyl cellulose 1 α01 Tragacanth gum 5.02 Vaseline
55.5 f liquid paraffin 10
02 Paraffin 4,0210 (L
OP Example 6 According to Example 1, an ointment with the following formulation was prepared.
（処 方）(How to treat)
Claims (1)
ス、ポリビニルピロリドン、プルランおよびトラガント
ゴムよりなる群から選んだ１種または２種以上の化合物
を常用の軟膏基剤に配合した痔疾用軟膏。1) An ointment for hemorrhoids containing one or more compounds selected from the group consisting of polyvinyl alcohol, pectin, methylcellulose, polyvinylpyrrolidone, pullulan, and gum tragacanth in a commonly used ointment base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60053000A JPS61212515A (en) | 1985-03-16 | 1985-03-16 | Ointment for hemorrhoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60053000A JPS61212515A (en) | 1985-03-16 | 1985-03-16 | Ointment for hemorrhoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS61212515A true JPS61212515A (en) | 1986-09-20 |
Family
ID=12930652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60053000A Pending JPS61212515A (en) | 1985-03-16 | 1985-03-16 | Ointment for hemorrhoid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61212515A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0979654A4 (en) * | 1998-03-04 | 2002-05-08 | Teijin Ltd | Activated vitamin d 3 emulsion-type lotions |
| JP2005343891A (en) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2005343890A (en) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2006282559A (en) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | Dispersion-based ointment for hemorrhoid treatment having excellent sense of use and high-temperature stability |
| US7459288B2 (en) | 2002-11-11 | 2008-12-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method of producing retinyl esters |
| JP2014031377A (en) * | 2013-09-30 | 2014-02-20 | Masanori Somei | Composition containing n-acyl tryptamine |
| JP2021522267A (en) * | 2018-04-25 | 2021-08-30 | フェリング・ベー・フェー | Topical pharmaceutical composition for the treatment of anal fissure and hemorrhoids |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5489017A (en) * | 1977-12-26 | 1979-07-14 | Lion Dentifrice Co Ltd | Ointment agent |
| JPS5512885A (en) * | 1978-05-09 | 1980-01-29 | Alsacienne Constr Meca | Spinning method and apparatus by rotary ring |
| JPS5831212A (en) * | 1981-08-18 | 1983-02-23 | Nakajima Tekkosho:Kk | Small size incinerator |
| JPS58206534A (en) * | 1982-05-26 | 1983-12-01 | Taisho Pharmaceut Co Ltd | Base for oral cavity drug |
| JPS5962518A (en) * | 1982-10-01 | 1984-04-10 | Shinsei Yakuhin Kogyo Kk | External drug for topical application and its preparation |
-
1985
- 1985-03-16 JP JP60053000A patent/JPS61212515A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5489017A (en) * | 1977-12-26 | 1979-07-14 | Lion Dentifrice Co Ltd | Ointment agent |
| JPS5512885A (en) * | 1978-05-09 | 1980-01-29 | Alsacienne Constr Meca | Spinning method and apparatus by rotary ring |
| JPS5831212A (en) * | 1981-08-18 | 1983-02-23 | Nakajima Tekkosho:Kk | Small size incinerator |
| JPS58206534A (en) * | 1982-05-26 | 1983-12-01 | Taisho Pharmaceut Co Ltd | Base for oral cavity drug |
| JPS5962518A (en) * | 1982-10-01 | 1984-04-10 | Shinsei Yakuhin Kogyo Kk | External drug for topical application and its preparation |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0979654A4 (en) * | 1998-03-04 | 2002-05-08 | Teijin Ltd | Activated vitamin d 3 emulsion-type lotions |
| CZ298971B6 (en) * | 1998-03-04 | 2008-03-26 | Teijin Limited | Lotions based on Active vitamin D3 emulsions |
| US7459288B2 (en) | 2002-11-11 | 2008-12-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method of producing retinyl esters |
| US8030352B2 (en) | 2002-11-11 | 2011-10-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Method of producing retinyl esters |
| JP2005343891A (en) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2005343890A (en) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | Skin care preparation for external use |
| JP2006282559A (en) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | Dispersion-based ointment for hemorrhoid treatment having excellent sense of use and high-temperature stability |
| WO2006112038A1 (en) * | 2005-03-31 | 2006-10-26 | Kobayashi Pharmaceutical Co., Ltd. | Dispersion ointment for treatment of hemorrhoids excellent in feeling after application and stability at high temperatures |
| JP2014031377A (en) * | 2013-09-30 | 2014-02-20 | Masanori Somei | Composition containing n-acyl tryptamine |
| JP2021522267A (en) * | 2018-04-25 | 2021-08-30 | フェリング・ベー・フェー | Topical pharmaceutical composition for the treatment of anal fissure and hemorrhoids |
| US11865207B2 (en) | 2018-04-25 | 2024-01-09 | Ferring B.V. | Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3065530B2 (en) | Pharmaceutical base, pharmaceutical preparation method, pharmaceutical composition, drug, pharmaceutical material and cosmetic product | |
| US5061700A (en) | Glyceryl acetate ointment vehicles | |
| JP2001026550A (en) | No-imparting material for treating anal disease and treatment by the same | |
| US3924004A (en) | Fatty alcohol-propylene carbonate-glycol solvent cream vehicle | |
| JP4209467B2 (en) | Formulation composition for oral administration | |
| PT92148B (en) | METHOD FOR PREPARING A GUM CONTAINING CHOLESTEROL FOR THE TOPICAL TREATMENT OF DERMATOSES | |
| JPS61212515A (en) | Ointment for hemorrhoid | |
| EP0848948B1 (en) | Long-lasting composition for rectal administration | |
| EP0784975A1 (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
| JPH07304669A (en) | Hemorrhoid therapeutic composition | |
| KR20020038595A (en) | Topical Formulations Comprising Skin Penetration Agents and the Use Thereof | |
| JPH06219942A (en) | Gelatin capsule preparation mixed with tranexamic acid | |
| JPS6218526B2 (en) | ||
| US3068148A (en) | Cis-cinnamic acid anti-inflammatory compositions and process of treating inflammation and capillary fragility | |
| JPS63216817A (en) | Gelatinous composition | |
| Khan | Extemporaneous compounding of medicated ointments | |
| JPS58177916A (en) | External drug | |
| JP4651132B2 (en) | Composition for continuous rectal administration | |
| JPS61109710A (en) | Suppository for hemorrhoids | |
| JP3740701B2 (en) | Anti-inflammatory analgesic topical | |
| JPH0133443B2 (en) | ||
| RU2120305C1 (en) | Pharmaceutical composition showing antifungal activity and a method of its preparing | |
| JPS60218318A (en) | Composition for filling in soft capsule | |
| US2484035A (en) | Trichomonadicidal therapeutic composition | |
| WO2021057694A1 (en) | Low-content flurbiprofen axetil pharmaceutical composition, and application thereof |